Glimsentro-PG1 Tablet SR is a fixed-dose combination medication containing Glimepiride 1mg, Metformin 500mg, and Pioglitazone 15mg, indicated for the management of type 2 diabetes mellitus. This formulation combines three distinct antidiabetic agents with complementary mechanisms of action to improve glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which enhances insulin sensitivity in adipose tissue, muscle, and the liver. The sustained-release (SR) formulation allows for once-daily dosing, promoting patient adherence and providing stable plasma drug concentrations. Glimsentro-PG1 is prescribed as an adjunct to diet and exercise to achieve optimal glycemic control in patients inadequately controlled on monotherapy or dual therapy. Caution is advised in patients with hepatic or renal impairment, heart failure, or a history of bladder cancer. Regular monitoring of blood glucose, liver function tests, and cardiovascular status is recommended during therapy. This combination therapy offers a comprehensive approach to managing hyperglycemia in type 2 diabetes.